Annie De Groot
Research Professor and Director, Institute for Immunology and Informatics
Office: 80 Washington Street, Providence, R.I.
Telephone: (401) 277-5408
- M.D. University of Chicago, 1983
Vaccine discovery and protein deimmunization
Dr. De Groot earned degrees from Smith College (BA, 1978) and the Pritzker School of Medicine at the University of Chicago (MD, 1983). She was trained in internal medicine at New England Medical Center (1986), and then went on to complete additional training in immunoinformatics and vaccine research under Jay Berzofsky at the NIH (1989). Following her fellowship at the NIH, she returned to NEMC for clinical training in infectious disease (1991). She was board certified in Internal Medicine in 1986 and in Infectious Disease in 1992. In 1992, she joined the faculty of the Brown University Medical School, where she opened the TB/HIV Research Laboratory. She designed the EpiMatrix algorithm at Brown University with the assistance of Gabe Meister, Bill Jesdale and Bill Martin. With Bill, she founded EpiVax, Inc. in 1998 and licensed the EpiMatrix technology. She has been the CEO/CSO and President of EpiVax since 1998. At EpiVax, Dr. De Groot supervises the science and business strategies at EpiVax.
She spends one per week on academic pursuits at Brown University, where she is Associate Professor of Medicine and Community Health and at University of Rhode Island where she teaches vaccinology to undergraduate students (Spring Semester) and provides clinical care to patients at the Rhode Island TB clinic one afternoon per week. She founded and edited IDCR (1998-2008) and is founder and Scientific Director of the GAIA Vaccine Foundation (501c3, 2002). In addition to her active research on vaccines, she is a pioneer in the field of deimmunisation (of protein therapeutics). She and Bill Martin developed the DeFT approach to reengineering protein pharmaceuticals in 2002 and discovered “Epi-13″ also known as “Tregitope”, new molecules with potential for the treatment of autoimmune diseases, in 2007. De Groot has received more than $26 million in uninterrupted federal funding for her research activities through multiple NIH (K08, R21, R01, SBIR) and foundation grants since 1989. She was the recipient of a National Foundation for Infectious Diseases-Eli Lilly Award, two Rhode Island Foundation awards and a Commercial Innovation Award (from the Rhode Island Center for Cellular Medicine).
In 2003 she was recognized by Women and Infants Hospital as “Woman of the Year in Science”. She was recognized as one of the “Best and the Brightest” in Science and Technology by Esquire Magazine (2003) for her work on the GAIA HIV vaccine. In 2006 she was named “Doctor of the Year” by the Rhode Island Medical Women’s Association. In 2007 she received the Al Fisher “Red Ribbon Award” for her AIDS work in West Africa, from AIDS Project Rhode Island. She has published more than 100 articles and chapters describing the development of epitope-driven vaccines and the application of immunoinformatics tools. She nourished a productive laboratory (the TB/HIV Research Laboratory) at Brown before shifting her primary effort from Brown to EpiVax in 2006. As CEO of EpiVax, she successfully established client relationships with Amgen, Eli Lilly, Wyeth, Pfizer, Roche, Abbott and a range of smaller biotech companies. In 2009, she was awarded a $13 million grant from the NIH to set up the Institute for Immunology and Informatics at the University of Rhode Island, where she is also a Research Professor. As Principal Investigator of the grant, Dr. De Groot also leads the Multi-Path project which focuses on developing a vaccine against mutiple bioterror agents.
- An integrated genomic and immunoinformatic approach to H. pylori vaccine design. Ardito M, Fueyo J, Tassone R, Terry F, DaSilva K, Zhang S, Martin W, De Groot AS, Moss SF, Moise L. Immunome Res. 2011
- Species neutral correlates of immunogenicity for vaccines and protein therapeutics: fact or science fiction. De Groot AS, Baker M, Cohen T. Hum Vaccin. 2010
- A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). Cohen T, Moise L, Ardito M, Martin W, De Groot AS. J Biomed Biotechnol. 2010
- VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS. Vaccine. 2011
- Harnessing the power of genomics and immunoinformatics to produce improved vaccines. Moise L, Cousens L, Fueyo J, De Groot AS. Expert Opin Drug Discov. 2011
- HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. Vaccine. 2011
- Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, Drake DR 3rd. Vaccine. 2011
- Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Elyaman W, Khoury SJ, Scott DW, De Groot AS. Neurol Res Int. 2011
- Time for T?: Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines. De Groot AS, McClaine E, Moise L, Martin W. Hum Vaccin. 2010
- A comparison of two methods for T cell epitope mapping: “cell free” in vitro versus immunoinformatics. Messitt TJ, Terry F, Moise L, Martin W, De Groot AS. Immunome Res. 2011
- Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Levitz L, Koita OA, Sangare K, Ardito MT, Boyle CM, Rozehnal J, Tounkara K, Dao SM, Koné Y, Koty Z, Buus S, Moise L, Martin WD, De Groot AS. Vaccine. 2012
- Clínica Esperanza/Hope Clinic clinical outcomes review: February-July 2011. Bicki A, Rogers R, Velasquez V, De Groot AS. Med Health R I. 2011
- Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Clin Immunol. 2012
- New vaccines needed for pathogens infecting animals and humans: One Health. Gutiérrez AH, Spero D, Gay C, Zimic M, De Groot AS. Hum Vaccin Immunother. 2012
- Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. De Groot AS, Levitz L, Ardito MT, Skowron G, Mayer KH, Buus S, Boyle CM, Martin WD. Hum Vaccin Immunother. 2012
- In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity. Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS. J Clin Immunol. 2012
- Tregitope update: Mechanism of action parallels IVIg. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Autoimmun Rev. 2012
- Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, Meijer SL, van Deventer SJ, Petry H, Hommes DW, Ferreira V. World J Gastroenterol. 2012
- Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Cousens L, Mignozzi F, van der Marel S, Su Y, Garman R, Ferreira V, Martin W, Scott DW, De Groot AS. Hum Vaccin Immunother. 2012
- Immunogenic consensus sequence T helper epitopes for a pan-Burkholderia biodefense vaccine. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero D, Tejada G, Martin W. Immunome Res. 2011